Myeloma bone disease: Pathogenetic mechanisms and clinical assessment
Authors:
- Franco SilvestrisFSFranco Silvestris
- Lucia LombardiLLLucia Lombardi
- Monica De MatteoMMMonica De Matteo
- Arianna BrunoABArianna Bruno
- Franco DammaccoFDFranco Dammacco
- 1 February 2007
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 31 (2) , 129-138
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Functional osteoclast‐like transformation of cultured human myeloma cell linesBritish Journal of Haematology, 2005
- Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cellsBritish Journal of Haematology, 2004
- Pathogenesis of myeloma bone diseaseBlood Cells, Molecules, and Diseases, 2004
- The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple MyelomaNew England Journal of Medicine, 2003
- New insights into the pathophysiology and management of bone disease in multiple myelomaBritish Journal of Haematology, 2003
- RANK ligand and osteoprotegerin in myeloma bone diseaseBlood, 2003
- Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsBlood, 2002
- Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone diseaseBlood, 2001
- Myeloma bone diseaseSeminars in Hematology, 2001
- Evidence for the Secretion of an Osteoclast Stimulating Factor in MyelomaNew England Journal of Medicine, 1974